New study tests if 3D MRI outperforms ruler for breast tumor measurement
NCT ID NCT07268300
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to see if MRI can measure breast tumor volume more accurately than the usual one-dimensional ruler method. About 59 women with suspicious or confirmed breast cancer will get an MRI before surgery, and the MRI-based tumor volume will be compared to the actual tumor size measured after removal. The goal is to improve treatment planning and response tracking.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 59 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Dec 2025
An estimate. Start dates often move.
- Expected to finish
-
Oct 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Female patients aged between 18 and 65 years old.BIRADS classification IV, V, or VI with Operable breast cancer.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Female patients aged between 18 and 65 years old. * BIRADS classification IV, V, or VI * Operable breast cancer. * 1st presentation. Exclusion Criteria: * Patients with contraindication for MRI imaging including heart pacemaker * Patients with contrast media allergy. * Prior history of breast cancer in the same breast with recurrence. * Inflammatory carcinoma. * Paget disease of the nipple
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Retrospective analysis of pyrotinib in the treatment of HER2-Positive advanced breast cancer previously treated with trastuzumab and pertuzumab
- Mind and body: does resilience leave a molecular mark in breast cancer?
- Which pain block works better for breast surgery?
- Can a Triple-Drug combo erase HER2-Positive breast tumors before surgery?
- Bacteria inside tumors may hold the key to breast cancer treatment
- Can a newer drug ease the bone pain of chemotherapy support?